Primary systemic chemotherapy of breast cancer: indication and predictive factors (Q37801866)

23 August 2017

title

Primary systemic chemotherapy of breast cancer: indication and predictive factors (English)

1 reference

23 August 2017

1 reference

Hiromitsu Jinno

1

1 reference

23 August 2017

Michio Sakata

2

1 reference

23 August 2017

Tetsu Hayashida

3

1 reference

23 August 2017

Maiko Takahashi

4

1 reference

23 August 2017

Tomomi Sato

5

1 reference

23 August 2017

Hirohito Seki

6

1 reference

23 August 2017

Yuko Kitagawa

7

1 reference

23 August 2017

publication date

21 October 2010

1 reference

23 August 2017

1 reference

23 August 2017

volume

18

1 reference

23 August 2017

issue

2

1 reference

23 August 2017

page(s)

74-79

1 reference

https://scigraph.springernature.com/pub.10.1007/s12282-010-0226-5

23 August 2017

exact match

0 references

cites work

Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27.

1 reference

https://api.crossref.org/works/10.1007%2FS12282-010-0226-5

Preoperative chemotherapy is safe in early breast cancer, even after 10 years of follow-up; clinical and translational results from the EORTC trial 10902.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12282-010-0226-5

Invasive pneumococcal disease among infants before and after introduction of pneumococcal conjugate vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12282-010-0226-5

Oestrogen receptor status, pathological complete response and prognosis in patients receiving neoadjuvant chemotherapy for early breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12282-010-0226-5

A phase II trial of capecitabine and docetaxel followed by 5-fluorouracil/epirubicin/cyclophosphamide (FEC) as preoperative treatment in women with stage II/III breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12282-010-0226-5

Chemotherapy is more effective in patients with breast cancer not expressing steroid hormone receptors: a study of preoperative treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12282-010-0226-5

Invasive lobular carcinoma classic type: response to primary chemotherapy and survival outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12282-010-0226-5

Invasive ductal carcinoma and invasive lobular carcinoma of breast differ in response following neoadjuvant therapy with epidoxorubicin and docetaxel + G-CSF.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12282-010-0226-5

Clinical response after two cycles compared to HER2, Ki-67, p53, and bcl-2 in independently predicting a pathological complete response after preoperative chemotherapy in patients with operable carcinoma of the breast

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12282-010-0226-5

ERBB2 and TOP2A in breast cancer: a comprehensive analysis of gene amplification, RNA levels, and protein expression and their influence on prognosis and prediction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12282-010-0226-5

Gene expression profiling of breast cancer patients treated with docetaxel, doxorubicin, and cyclophosphamide within the GEPARTRIO trial: HER-2, but not topoisomerase II alpha and microtubule-associated protein tau, is highly predictive of tumor res

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12282-010-0226-5

A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12282-010-0226-5

Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12282-010-0226-5

Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12282-010-0226-5

Gene expression profiles predict complete pathologic response to neoadjuvant paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide chemotherapy in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12282-010-0226-5

Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12282-010-0226-5

Gene expression signature predicting pathologic complete response with gemcitabine, epirubicin, and docetaxel in primary breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12282-010-0226-5

Neoadjuvant vinorelbine-capecitabine versus docetaxel-doxorubicin-cyclophosphamide in early nonresponsive breast cancer: phase III randomized GeparTrio trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12282-010-0226-5

Neoadjuvant chemotherapy in breast cancer: significantly enhanced response with docetaxel

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12282-010-0226-5

10.1007/S12282-010-0226-5

21 January 2018

Identifiers

DOI

1 reference

23 August 2017

1 reference